Veradermics(NYSE) MANE

Veradermics makes medicines for common skin and hair problems. It helps adults and children struggling with chronic hair loss. The company also creates treatments for warts and skin infections.

The Science of Skin and Hair

• VDPHL01: Oral, nonhormonal medication for men and women with pattern hair loss, a condition where hair thins over time.
• VDMN: Dissolvable patch that uses the immune system to treat common warts.
• VDAA: Experimental drug candidate for alopecia areata, an autoimmune condition that causes hair to fall out in patches.
• VDMC: Clinical-stage treatment for molluscum contagiosum, which is a viral skin infection that typically affects children.

Recent Milestones and Funding

• Raised $269.1 million in net proceeds through an initial public offering on Feb. 4, 2026.
• Secured $414.3 million in net proceeds from a follow-on public offering in May 2026.
• Closed a private sale of warrants in May 2026 for net proceeds of $28.1 million.
• Reported positive Phase 2/3 trial data for its male hair loss treatment in April 2026.
• Finished enrolling patients for a registration-directed study of its female hair loss treatment in mid-2026.

Solving Problems With New Tools

Veradermics uses extended-release technology, which releases medicine slowly over several hours. This design aims to provide better hair growth while reducing the risk of heart-related side effects compared to traditional pills.

Tracking the Financial Progress

• Net loss was $50.7 million for the six-month period ended June 30, 2026, compared to $28.0 million for the same period in 2025.
• Research and development expenses rose by $13.8 million for the six-month period ended June 30, 2026.
• General and administrative costs hit $19.9 million for the six-month period ended June 30, 2026, an increase of $16.7 million year over year.
• Net cash used in operating activities was $35.7 million for the six-month period ended June 30, 2026.
• Cash, cash equivalents, and marketable securities totaled $819.9 million as of June 30, 2026.

The Path Ahead

Veradermics has evolved from a private research firm into a public company with significant capital for late-stage clinical trials. Its progress depends on gaining regulatory approval for its lead candidates and preparing for commercial launches in the dermatology market.